Hsu S.-H.Chih A.-H.Lee Y.-C.KUO-CHIN HUANGCHYI-FENG JAN2021-01-142021-01-1420171478-3223https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018268603&doi=10.1111%2fliv.13437&partnerID=40&md5=c4b3b7fe8ee9aba045b53c59daf2e2echttps://scholars.lib.ntu.edu.tw/handle/123456789/540645Background & Aim: The aim of this study was to compare the long-term efficacy of infant recombinant yeast hepatitis B vaccine (Recombinant group) and infant plasma-derived one (Plasma group) in Taiwanese freshers. Methods: Recruited were a total of 38?377 freshmen who underwent university entrance health examinations from 2003 to 2015. Subjects were assigned into two groups—plasma type and recombinant type, according to the national neonatal hepatitis B immunization program. The seroprevalences of hepatitis B surface antigen, antibody against hepatitis B surface antigen, and antibody against hepatitis B core antigen in each group and gender were calculated. Multivariate logistic regression analysis was performed to compare the efficacy of two groups. Results: The HBsAg-positive rates in the plasma group and recombinant group were 1.5% and 0.3% respectively. The anti-HBs positive rates were 43.6% and 30.9%. The hepatitis B viral natural infection rates were 3.6% and 1.3%. Taking those who were born in July 1986-April 1992 as baseline group after adjustment for gender and age at hepatitis B markers checkup time, the efficacy of recombinant group in decreasing HBsAg positive rate, and decreasing hepatitis B virus natural infection rate was 71.0% (95% C.I.: 59.0-79.0%, P<.001) and 65.0% (95% C.I. 58.0-71.0%, P<.001) respectively. On the contrary, the seroprevalence of anti-HBs positive rate in recombinant group was 39.0% (95% C.I.: 36.0-42.0%, P<.001) lower than that of plasma group. (P<.001). Conclusion: Higher disappearance rate of anti-HBs was noted in recombinant group than in plasma group when the subjects reached their youth and young adulthood in Taiwan. ? 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd[SDGs]SDG3hepatitis B core antibody; hepatitis B core antigen; hepatitis B surface antibody; hepatitis B surface antigen; hepatitis B vaccine; plasma derived hepatitis B vaccine; recombinant yeast hepatitis B vaccine; unclassified drug; hepatitis B antibody; hepatitis B antigen; hepatitis B vaccine; recombinant vaccine; adult; antibody titer; Article; drug efficacy; female; hepatitis B; human; infection rate; major clinical study; male; medical examination; seroprevalence; Taiwanese; vaccination; young adult; adolescent; blood; comparative study; immunology; infant; newborn; retrospective study; statistics and numerical data; vaccination; Adolescent; Female; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B Vaccines; Humans; Infant; Infant, Newborn; Male; Retrospective Studies; Vaccination; Vaccines, Synthetic; Young Adultjournal article10.1111/liv.13437283749062-s2.0-85018268603